Longevity Health Holdings, Inc. - Common Stock (XAGE)
0.1779
+0.00 (0.00%)
NASDAQ · Last Trade: Apr 16th, 5:34 AM EDT
Detailed Quote
Previous Close | 0.1779 |
---|---|
Open | - |
Bid | 0.1573 |
Ask | 0.1660 |
Day's Range | N/A - N/A |
52 Week Range | 0.1000 - 0.4418 |
Volume | 97,713 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 14,271,523 |
Chart
News & Press Releases
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Longevity Health Holdings, Inc. (NasdaqCM: XAGE) and 20/20 BioLabs, Inc. Upon closing of the proposed transaction, Longevity shareholders are expected to own approximately 49.9% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Longevity shareholders.
By Kahn Swick & Foti, LLC · Via Business Wire · April 15, 2025
Via Benzinga · April 15, 2025
Longevity announced it entered into a merger agreement with 20/20 BioLabs.
Via Benzinga · April 14, 2025
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Longevity Health Holdings, Inc. (NASDAQ: XAGE) and 20/20 BioLabs, Inc. is fair to Longevity shareholders. Upon closing of the proposed transaction, Longevity shareholders are expected to own approximately 49.9% of the combined company.
By Halper Sadeh LLC · Via Business Wire · April 14, 2025
Via Benzinga · April 14, 2025
Via Benzinga · April 11, 2025
Via Benzinga · April 3, 2025
Via Benzinga · March 27, 2025
Via Benzinga · March 19, 2025
Via Benzinga · March 13, 2025